An interventional study of On-couch adaptive radiotherapy in Rectal Cancer, sponsored by Haukeland University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-19.
Sponsored by Haukeland University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Rectal Neoplasms with a site in Norway — 6 open to participants now, 12 under way, 3 of them phase 3. Rectal Neoplasms · Norway.
Among the 25 studies in Rectal Neoplasms with a site in Norway, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 4 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 24th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →6 of the 25 studies in Rectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:
San Raffaele University · Sites in Norway, United States, Finland and 3 more countries
Ages 18–49 · Healthy volunteers
The Hospital of Vestfold · Sites in Norway
Ages 18–99
Oslo University Hospital · Sites in Norway
Ages 18+
Catharina Ziekenhuis Eindhoven · Sites in Norway, Belgium, Netherlands and 2 more countries
Ages 18+
Helse Stavanger HF · Sites in Norway
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 61 is close to the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 106 across the 13 interventional studies, 192 across the 11 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 25 have an industry lead sponsor. The 10 most frequent:
Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 58 are open to participants now.
Haukeland University Hospital has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Neoplasms with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT05883800Haukeland University HospitalTotal Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer | 2026-12-31 |
| NCT04512937Oslo University HospitalComputer Navigation-assisted Surgery for Locally Advanced and Recurrent Rectal Cancer | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Rectal Neoplasms with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Diarrhea was the most frequently reported severe adverse event in the treatment regime of pre-operative sequential short-course radiotherapy followed by chemotherapy (so called total neo-adjuvant treatment).
This study therefore investigates the benefit of on-couch adaptation for locally advanced rectal cancer patients undergoing this treatment regime.
This is a prospective single-arm study investigating the benefit of on-couch adaptation for locally advanced rectal cancer patients prescribed with pre-operative sequential short-course radiotherapy (RT) followed by Oxaliplatin-combined chemotherapy (mFOLFOX(6) or CAPOX). On-couch adaptation, where the radiation dose is tailored to the anatomy of the patient at each radiotherapy session. Firstly, the study will investigate if on-couch adaptation result in less gastro-intestinal adverse events, secondly it will reveal if this possible reduction lead to more patients being able to fulfill all cycles of prescribed chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: daily on-couch adaptive radiotherapy
Radiation: On-couch adaptive radiotherapy
A new treatment plan, guided by volumetric images, is created at each treatment session
Also known as: online ART
Incidence of acute gastro-intestinal toxicity equal or higher than grade 2
Incidence of acute gastro-intestinal toxicity from therapy graded according to CTCAE ver. 5.
Time frame: Up to administration of the last course of chemotherapy or week 22, whichever comes first
Number of participants that require alteration of chemotherapy due to toxicity
Alterations of chemotherapy, defined as dose-reduction or pre-maturely stopping chemotherapy administration
Time frame: From treatment week 3 up to week 20
Number of patients with disease related treatment failure
Disease-related treatment failure include the first of any of the following events: (i) During treatment: Non-radical resection of primary tumor (R2 resection) or un-fit of for surgery due to progression, death from treatment (ii) During, or after treatment: Loco-regional recurrence (including regrowth after potential watch-and-wait), distant metastasis (including M re-staging at surgery), death from rectal cancer, second primary rectal cancer.
Time frame: 5 years after surgery
Number of patients with pathological complete response (pCR)
pCR after completion of the intended or tolerated TNT
Time frame: At surgery i.e. in treatment week 23-28
Tumour regression grade
Radiological based clinical response evaluation on MR (mrTRG)
Time frame: Baseline to response evaluation on MR in up to week 25 of the study
Overall survival
Overall survival from time of inclusion until death
Time frame: Follow-up until 5 years or death
Incidence of late gastro-intestinal toxicity equal or higher than grade 2
Incidence of late gastro-intestinal events (e.g.diarrhea, rectal hemorrhage, rectal and/or abdominal pain) from therapy graded according to CTCAE ver. 5.
Time frame: 5 years
Bowel exposure
Radiation dose to bowel
Time frame: Treatment week 1-2
Immunogenic alterations from TNT
Presence of selected immune cells
Time frame: Baseline and at surgery i.e. in treatment week 23-28
Perfusion changes on MR
Changes in perfusion from contrast-enhanced MR
Time frame: Baseline and at MR response evaluation up to week 25 of the study
Diffusion changes on MR
Changes in diffusion from diffusion-weighted MR
Time frame: Baseline and at MR response evaluation up to week 25 of the study
Patient reported general outcome measures
Quality of life using EORTC qlq-c30 questionnaire
Time frame: Baseline and up to 5 years of the study
Patient reported colo-rectal outcome measures
Quality of life using EORTC qlq-cr29 questionnaire
Time frame: Baseline and up to 5 years of the study
Patient reported bowel-related outcome measures
Quality of life using low anterior resection syndrome (LARS) score
Time frame: Baseline and up to 5 years of the study
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 42 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haukeland University Hospital →